Private Equity
Private Equity

Emergent BioSolutions Surges

Emergent BioSolutions Inc. (NYSE: EBS) waited until August to announce its first transactions of 2018, but its stock has been rising all year. On August 9, we reported the company acquired specialty vaccine maker PaxVax, Inc. for $270 million. EBS followed that up on August 28 with a $635 million deal for Adapt Pharma, maker of  Narcan® […]

PaxVax Changes Hands Again

Specialty vaccine maker PaxVax Inc. has changed owners again, more than doubling its equity value in two and a half years. The Redwood City, California-based company was acquired by Cerberus Capital Management in December 2015 for $105 million from Ignition Growth Capital and other investors. The sellers retained a minority stake, while Cerberus took the […]

Sanofi Rationalizes Its Vaccine Portfolio

Early in July, Sanofi (NYSE: SNY) announced an acquisition and a divestment, both affecting its vaccine business. In a recent annual filing, Sanofi labelled its vaccine unit as an area of priority to sustain its leadership role. To that end, the company has expanded its influenza vaccine portfolio and shed its small pox vaccine business, including […]